{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:15:49Z","timestamp":1791404149767,"version":"4.3.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40259-023-00630-5","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:02:26Z","timestamp":1700640146000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct04673786","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Kwiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Trefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-947X","authenticated-orcid":false,"given":"Nataliya","family":"Reznichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Narbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kolinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Daniluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bartnicka-Maslowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Andrashko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunju","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunseung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woori","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"630_CR2","unstructured":"European Medicines Agency. Stelara: Summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf. Accessed 30 May 2023."},{"key":"630_CR3","unstructured":"US Food & Drug Administration. Stelara: prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761044s010lbl.pdf. Accessed 30 May 2023."},{"issue":"6","key":"630_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535\u201345. https:\/\/doi.org\/10.4161\/mabs.3.6.17815.","journal-title":"MAbs"},{"issue":"5","key":"630_CR5","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.jaci.2019.01.017","volume":"143","author":"C Brodmerkel","year":"2019","unstructured":"Brodmerkel C, Li K, Garcet S, Hayden K, Chiricozzi A, Novitskaya I, et al. Modulation of inflammatory gene transcripts in psoriasis vulgaris: differences between ustekinumab and etanercept. J Allergy Clin Immunol. 2019;143(5):1965\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"630_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","volume":"42","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs. Drug Saf. 2019;42(6):751\u201368. https:\/\/doi.org\/10.1007\/s40264-019-00797-3.","journal-title":"Drug Saf"},{"issue":"9894","key":"630_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/s0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(13)60594-2.","journal-title":"Lancet"},{"issue":"4","key":"630_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844\u201354. https:\/\/doi.org\/10.1111\/bjd.12214.","journal-title":"Br J Dermatol"},{"issue":"6","key":"630_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"630_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"630_CR11","unstructured":"US Food & Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https:\/\/www.fda.gov\/media\/82647\/download. Accessed 30 May 2023."},{"key":"630_CR12","unstructured":"European Medicines Agency. Biosimilars in the EU: Information guide for healthcare professionals. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 30 May 2023."},{"key":"630_CR13","unstructured":"US Food & Drug Administration. Biosimilar product information. 2023. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 30 May 2023."},{"key":"630_CR14","unstructured":"European Medicines Agency. Medicines. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/search_api_aggregation_ema_medicine_types\/field_ema_med_biosimilar?search_api_views_fulltext=omalizumab. Accessed 30 May 2023."},{"issue":"9625","key":"630_CR15","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet"},{"issue":"9625","key":"630_CR16","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6.","journal-title":"Lancet"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Group TJUS. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol. 2012;39:242\u201352.\u00a0https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01347.x.","journal-title":"J Dermatol"},{"issue":"3","key":"630_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154\u201363. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.05.005.","journal-title":"J Dermatol Sci"},{"key":"630_CR19","first-page":"166","volume":"12","author":"H Zhu","year":"2013","unstructured":"Zhu H, Zheng M, Song M, Shen Y-K, Chan D, Szapary PO, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12:166\u201374.","journal-title":"J Drugs Dermatol"},{"key":"630_CR20","unstructured":"ClinicalTrials.gov. Study to compare PK and safety of subcutaneous injection of ustekinumab and CT-P43 in healthy subjects (NCT04428814). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04428814. Accessed 30 May 2023."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T09:24:59Z","timestamp":1705397099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00630-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"26 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Celltrion, Inc. (Incheon, Republic of Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.A. Papp has received grants for clinical studies from AbbVie, Akros, Amgen, Anacor, Arcutis, Avillion, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol\u00a0Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly, Evelo, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Merck (MSD), Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Sun Pharma, Takeda, and UCB; consulting fees from AbbVie, Acelyrin, Akros, Amgen, Aralez Pharmaceuticals, Arcutis, Avillion, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol\u00a0Myers Squibb, Can-Fite Biopharma, Celgene, Celltrion, Coherus, Dermavant, Dermira, Dice Pharmaceuticals, Dow Pharma, Eli Lilly, Evelo, Forbion, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Merck (MSD), Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; has participated in speakers bureaus for AbbVie, Amgen, Bausch Health\/Valeant, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Merck (MSD), Novartis, Pfizer, and Sanofi-Aventis\/Genzyme; has received honoraria for attending meetings and\/or travel from AbbVie, Acelyrin, Akros, Amgen, Aralez Pharmaceuticals, Bausch Health\/Valeant, Boehringer Ingelheim, Celgene, Celltrion, Coherus, Dermavant, Dice Pharmaceuticals, Eli Lilly, Forbion, Galderma, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Merck (MSD), Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; has served on advisory boards for AbbVie, Amgen, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol\u00a0Myers Squibb, Celgene, Dice Pharmaceuticals, Dow Pharma, Eli Lilly, Galderma, Janssen, Merck (MSD), Novartis, Pfizer, Regeneron, Sanofi-Aventis\/Genzyme, Sun Pharma, and UCB; has served as a scientific officer for Akros, Anacor, Arcutis, Dice Pharmaceuticals, Kyowa Hakko Kirin; and has served on steering committees for AbbVie, Amgen, Bausch Health\/Valeant, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck (MSD), Novartis, Pfizer, Regeneron, Reistone, and Sanofi-Aventis\/Genzyme. M.G. Lebwohl has received grants\/contracts from AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc.; and has received consulting fees from Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., Aristea Therapeutics, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer\u00a0Ingelheim, Bristol\u00a0Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dr. Reddy, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Helsinn, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, National Society for Cutaneous Medicine, Pfizer, Seanergy, Strata, Trevi, and Verrica, and Vial Health Technologies. D. Tha\u00e7i has received grants\/contracts from AbbVie, LEO Pharma and Novartis; received consulting fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma, MorphoSys, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Samsung, Sanofi and UCB; received honoraria from AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, LEO Pharma, MorphoSys, New-Bridge, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Samsung, Sandoz, Sanofi, Sun Pharma and UCB; and participated on data safety monitoring boards or advisory boards for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi and UCB.\u00a0A. Dudek has received grants for clinical trials from AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, GSK, Horizon, Janssen, UCB and VieLaBio. J.C. Szepietowski has received consulting fees from AbbVie, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Trevi, UCB and Vifor; and honoraria from AbbVie, Almirall, Janssen-Cilag, Eli Lilly, LEO Pharma, Novartis, Pfizer and Sanofi-Genzyme. N. Reznichenko has received grants for clinical trials from Alvotech, Argenx, Celltrion, Eli Lilly and Samsung. A. Reich has received grants for clinical trials from AnaptysBio, Argenx, Celltrion, Drug Delivery Solutions, Galderma, Genentech, Inflarx, Janssen, Kymab Ltd, LEO Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Trevi, Eli Lilly, UCB and VielaBio; and speaker fees from AbbVie, Bausch Health, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, LEO Pharma, Medac, Novartis, Pierre Fabre, Pfizer, Sandoz and Trevi. Y. Andrashko has received grants for clinical trials from Alfa Sigma, Alvotech, Amgen, Celltrion, Dong-A Pharmaceutical, Eli Lilly, Galderma, Mayne Pharma and Samsung Bioepis; and speaker fees from Blausch Health, Delta Medical, GSK, Novartis and Pfizer. S. Kim, Y. Bae, D. Jeon, J. Jung, H. Lee and T. Pyo are employees of Celltrion and own stocks in Celltrion. W. Ko is an employee of Celltrion. J. Jaworski, J. Trefler, J. Narbutt, W. Baran, J. Kolinek, S. Daniluk, K. Bartnicka-Maslowska and B. Kwiek report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data that support the findings of this study are available in the supplementary material of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable (no software or custom code).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study was conducted according to Good Clinical Practice and the principles of the Declaration of Helsinki, as well as national, state and local laws or regulations. Study materials were approved by independent ethics committee\/institutional review boards at each site.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients in this manuscript have given written informed consent for participation in the study and the use of their de-identified, anonymized, aggregated data and their case details (including photographs) for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable (no identifiable data).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"KAP, MGL, DT, SK, YB, DJ, JJ, HL, TP, and WK contributed to the study design. JJ, BK, JT, AD, JCS, NR, JN, WB, JK, SD, KB-M, AR and YA collected study data. All authors contributed to data analysis or interpretation, reviewed and critically revised the manuscript, provided final approval of the version to be published, and agree to be accountable for accuracy and integrity.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Selected data from the CT-P43 3.1 study were shared in an oral presentation at the 31st\u00a0European Academy of Dermatology and Venereology (EADV) congress (7\u201310 September 2022; Milan, Italy).","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Congress Presentations"}}]}}